JP2020514252A - Ｃｄｋ４／６媒介性がんを治療するための組成物および方法 - Google Patents
Ｃｄｋ４／６媒介性がんを治療するための組成物および方法 Download PDFInfo
- Publication number
- JP2020514252A JP2020514252A JP2019530811A JP2019530811A JP2020514252A JP 2020514252 A JP2020514252 A JP 2020514252A JP 2019530811 A JP2019530811 A JP 2019530811A JP 2019530811 A JP2019530811 A JP 2019530811A JP 2020514252 A JP2020514252 A JP 2020514252A
- Authority
- JP
- Japan
- Prior art keywords
- cdk4
- cancer
- alkyl
- mmol
- heterocyclyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y203/00—Acyltransferases (2.3)
- C12Y203/02—Aminoacyltransferases (2.3.2)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662431806P | 2016-12-08 | 2016-12-08 | |
| US62/431,806 | 2016-12-08 | ||
| PCT/US2017/065027 WO2018106870A1 (en) | 2016-12-08 | 2017-12-07 | Compositions and methods for treating cdk4/6-mediated cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020514252A true JP2020514252A (ja) | 2020-05-21 |
| JP2020514252A5 JP2020514252A5 (https=) | 2021-01-28 |
Family
ID=62491322
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019530811A Pending JP2020514252A (ja) | 2016-12-08 | 2017-12-07 | Ｃｄｋ４／６媒介性がんを治療するための組成物および方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11541051B2 (https=) |
| EP (1) | EP3551185A4 (https=) |
| JP (1) | JP2020514252A (https=) |
| CN (1) | CN110267659A (https=) |
| AU (1) | AU2017370694A1 (https=) |
| CA (1) | CA3045037A1 (https=) |
| WO (1) | WO2018106870A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023535054A (ja) * | 2020-07-21 | 2023-08-15 | ユービックス セラピューティクス インコーポレイテッド | アンドロゲン受容体分解用化合物及びその医薬用途 |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2968290T3 (da) * | 2013-03-15 | 2019-11-25 | G1 Therapeutics Inc | Transient beskyttelse af normale celler under kemoterapi |
| WO2018005863A1 (en) * | 2016-07-01 | 2018-01-04 | G1 Therapeutics, Inc. | Pyrimidine-based compounds for the treatment of cancer |
| EP3858835A1 (en) | 2016-07-01 | 2021-08-04 | G1 Therapeutics, Inc. | Pyrimidine-based antiproliferative agents |
| EP3532464A4 (en) | 2016-10-28 | 2020-07-08 | Icahn School of Medicine at Mount Sinai | COMPOSITIONS AND METHODS FOR THE TREATMENT OF EZH2 MEDIATION CANCER |
| JP2020514252A (ja) | 2016-12-08 | 2020-05-21 | アイカーン スクール オブ メディスン アット マウント シナイ | Ｃｄｋ４／６媒介性がんを治療するための組成物および方法 |
| US11173211B2 (en) | 2016-12-23 | 2021-11-16 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides |
| TWI791552B (zh) | 2017-07-10 | 2023-02-11 | 美商西建公司 | 抗增生化合物及其使用方法 |
| CN109516989B (zh) * | 2017-09-17 | 2021-12-31 | 上海美志医药科技有限公司 | 一类抑制并降解cdk的化合物 |
| EP3728228A1 (en) | 2017-12-22 | 2020-10-28 | Ravenna Pharmaceuticals, Inc. | Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors |
| CA3092677A1 (en) | 2018-03-06 | 2019-09-12 | Icahn School Of Medicine At Mount Sinai | Serine threonine kinase (akt) degradation / disruption compounds and methods of use |
| US12539292B2 (en) | 2018-04-01 | 2026-02-03 | Arvinas Operations, Inc. | BRM targeting compounds and associated methods of use |
| CN118344338A (zh) | 2018-04-23 | 2024-07-16 | 细胞基因公司 | 取代的4-氨基异吲哚啉-1,3-二酮化合物以及它们用于治疗淋巴瘤的用途 |
| WO2019242625A1 (zh) * | 2018-06-20 | 2019-12-26 | 上海科技大学 | 制备来那度胺衍生物的方法 |
| CA3104298A1 (en) | 2018-06-21 | 2019-12-26 | Icahn School Of Medicine At Mount Sinai | Wd40 repeat domain protein 5 (wdr5) degradation / disruption compounds and methods of use |
| EP3817745A4 (en) * | 2018-07-05 | 2022-04-06 | Icahn School of Medicine at Mount Sinai | PROTEIN TYROSINE KINASE 6 (PTK6) DEGRADATION/DISPUTED COMPOUNDS AND METHODS OF USE |
| WO2020023502A1 (en) * | 2018-07-23 | 2020-01-30 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| CN108948136A (zh) * | 2018-08-06 | 2018-12-07 | 浙江华海药业股份有限公司 | 一种赖诺普利杂质及其制备方法 |
| CN110835345A (zh) * | 2018-08-17 | 2020-02-25 | 中国科学院上海药物研究所 | 一类细胞周期依赖性激酶的降解剂、其制备方法、药物组合物及其用途 |
| EP3841100A1 (en) | 2018-08-20 | 2021-06-30 | Arvinas Operations, Inc. | Proteolysis targeting chimeric (protac) compound with e3 ubiquitin ligase binding activity and targeting alpha-synuclein protein for treating neurodegenerative diseases |
| KR20210072043A (ko) * | 2018-10-08 | 2021-06-16 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | 소분자 mdm 2 단백질 분해제 |
| JP7600123B2 (ja) * | 2018-10-15 | 2024-12-16 | ニューリックス セラピューティクス，インコーポレイテッド | ユビキチンプロテオソーム経路を介してｂｔｋを分解するための二官能性化合物 |
| WO2020092662A1 (en) * | 2018-11-02 | 2020-05-07 | The Wistar Institute Of Anatomy And Biology | Proteolysis-targeting chimeras |
| CN111205282B (zh) * | 2018-11-21 | 2023-12-01 | 上海科技大学 | Er蛋白调节剂及其应用 |
| WO2020163823A2 (en) * | 2019-02-08 | 2020-08-13 | University Of Florida Research Foundation, Incorporated | Therapeutic agents and methods of treatment |
| WO2020167518A1 (en) | 2019-02-13 | 2020-08-20 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
| CN113646002A (zh) * | 2019-02-27 | 2021-11-12 | 上海睿跃生物科技有限公司 | 环amp反应元件结合蛋白(cbp)和/或300kda腺病毒e1a结合蛋白(p300)降解化合物和使用方法 |
| KR20210141554A (ko) | 2019-03-21 | 2021-11-23 | 코디악 바이오사이언시즈, 인크. | 세포외 소포 접합체 및 이의 용도 |
| WO2020191369A1 (en) | 2019-03-21 | 2020-09-24 | Codiak Biosciences, Inc. | Process for preparing extracellular vesicles |
| AU2020247255A1 (en) * | 2019-03-28 | 2021-11-11 | Essa Pharma, Inc. | Androgen receptor modulators and methods for use as Proteolysis Targeting Chimera ligands |
| US11485735B2 (en) * | 2019-04-25 | 2022-11-01 | Wuxi Shuangliang Biotechnology Co., Ltd. | Selective CDK4/6 inhibitor and preparation thereof |
| CN118908962A (zh) * | 2019-05-06 | 2024-11-08 | 西奈山伊坎医学院 | 作为hpk1的降解剂的异双功能化合物 |
| US12605452B2 (en) * | 2019-06-03 | 2026-04-21 | Regents Of The University Of Minnesota | Compounds that degrade kinases and uses thereof |
| TW202112767A (zh) | 2019-06-17 | 2021-04-01 | 美商佩特拉製藥公司 | 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物 |
| CN119954801A (zh) | 2019-07-17 | 2025-05-09 | 阿尔维纳斯运营股份有限公司 | Tau蛋白靶向化合物及相关使用方法 |
| ES3031581T3 (en) * | 2019-08-05 | 2025-07-09 | Dana Farber Cancer Inst Inc | Degraders of cyclin-dependent kinase 7 (cdk7) and uses thereof |
| CN112457365B (zh) * | 2019-09-09 | 2023-06-09 | 中国医学科学院药物研究所 | 一类靶向蛋白质水解通路的功能分子及其制备和应用 |
| CN115397821B (zh) | 2019-10-17 | 2024-09-03 | 阿尔维纳斯运营股份有限公司 | 含有与bcl6靶向部分连接的e3泛素连接酶结合部分的双官能分子 |
| US11820781B2 (en) | 2019-12-04 | 2023-11-21 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway |
| MX2022007487A (es) | 2019-12-16 | 2022-08-04 | Lunella Biotech Inc | Agentes terapeuticos selectivos contra el cancer inhibidores de cdk4/6. |
| CR20220342A (es) * | 2019-12-16 | 2023-01-23 | Lunella Biotech Inc | Agentes terapéuticos selectivos contra el cáncer inhibidores cdk4/6 |
| JP2023508891A (ja) * | 2019-12-17 | 2023-03-06 | オリオニス バイオサイエンシズ，インコーポレイテッド | タンパク質の動員および／または分解のための二機能性剤 |
| JP2023507590A (ja) * | 2019-12-17 | 2023-02-24 | オリオニス バイオサイエンシズ，インコーポレイテッド | タンパク質の動員および／または分解を調節する化合物 |
| AU2021207672A1 (en) | 2020-01-15 | 2022-07-14 | University Of Florida Research Foundation, Incorporated | Therapeutic agents and methods of treatment |
| WO2021150945A1 (en) * | 2020-01-23 | 2021-07-29 | Icahn School Of Medicine At Mount Sinai | Methods of diagnosing and treating cancer |
| ES3048084T3 (en) | 2020-05-19 | 2025-12-09 | Pharmacosmos Holding As | Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders |
| WO2021237100A1 (en) | 2020-05-21 | 2021-11-25 | Codiak Biosciences, Inc. | Methods of targeting extracellular vesicles to lung |
| US12103924B2 (en) | 2020-06-01 | 2024-10-01 | Icahn School Of Medicine At Mount Sinai | Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use |
| US11964983B2 (en) * | 2020-06-11 | 2024-04-23 | Lunella Biotech, Inc. | Selective CDK4/6 inhibitor cancer therapeutics |
| EP4201406A4 (en) * | 2020-08-18 | 2024-08-28 | Daegu Gyeongbuk Institute Of Science and Technology | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF DEGENERATIVE BRAIN DISEASES COMPRISING ABEMACICLIB AS ACTIVE INGREDIENT |
| KR102601028B1 (ko) * | 2020-08-18 | 2023-11-10 | 재단법인대구경북과학기술원 | 아베마시클립을 유효성분으로 포함하는 퇴행성 뇌질환의 예방 또는 치료용 약학적 조성물 |
| JP7834721B2 (ja) | 2020-08-28 | 2026-03-24 | アルビナス・オペレーションズ・インコーポレイテッド | 急速進行性線維肉腫タンパク質分解化合物及び関連する使用方法 |
| US20240241020A1 (en) | 2020-09-23 | 2024-07-18 | Lonza Sales Ag | Process for preparing extracellular vesicles |
| CN114349738B (zh) * | 2020-10-14 | 2023-05-05 | 清华大学 | 一类靶向降解cdk2的小分子缀合物及其应用 |
| WO2022113003A1 (en) | 2020-11-27 | 2022-06-02 | Rhizen Pharmaceuticals Ag | Cdk inhibitors |
| WO2022149057A1 (en) | 2021-01-05 | 2022-07-14 | Rhizen Pharmaceuticals Ag | Cdk inhibitors |
| JP2024504932A (ja) | 2021-01-13 | 2024-02-02 | モンテ ローザ セラピューティクス， インコーポレイテッド | イソインドリノン化合物 |
| CN117279910A (zh) | 2021-04-16 | 2023-12-22 | 阿尔维纳斯运营股份有限公司 | Bcl6蛋白水解的调节剂和其相关使用方法 |
| AU2022379494A1 (en) | 2021-10-26 | 2024-05-30 | Nurix Therapeutics, Inc. | Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading btk |
| AU2022405474A1 (en) * | 2021-12-08 | 2024-07-18 | Gluetacs Therapeutics (Shanghai) Co., Ltd. | E3 ubiquitin ligase ligand compound, protein degrader developed based thereon and their applications |
| WO2023177451A1 (en) * | 2022-03-18 | 2023-09-21 | EnhancedBio Inc. | Compounds and methods for the targeted degradation of cyclin dependent kinases |
| TW202413356A (zh) * | 2022-05-10 | 2024-04-01 | 美商拜歐斯瑞克斯公司 | Ｃｄｋ蛋白降解劑、藥物組合物及其治療應用 |
| CN114957249B (zh) * | 2022-05-20 | 2023-04-21 | 东南大学 | 一种不可逆共价结合cdk抑制剂及其制备方法和应用 |
| EP4584258A1 (en) | 2022-09-07 | 2025-07-16 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use |
| CN120359217A (zh) * | 2022-09-15 | 2025-07-22 | 上海睿跃生物科技有限公司 | 经修饰的蛋白质以及蛋白质结合剂和降解剂 |
| WO2024086361A1 (en) * | 2022-10-21 | 2024-04-25 | Novartis Ag | Molecular glue degrader compounds and uses thereof |
| CN115650968B (zh) * | 2022-12-27 | 2023-03-21 | 英矽智能科技(上海)有限公司 | 作为cdk选择性抑制剂的新型哒嗪酮化合物 |
| EP4705307A1 (en) * | 2023-05-03 | 2026-03-11 | St. Jude Children's Research Hospital, Inc. | A sequence selective dna binding molecule (syngrader) |
| CN120981456A (zh) | 2023-05-24 | 2025-11-18 | 金橘生物科技公司 | 杂环化合物及其用途 |
| WO2024256569A1 (en) * | 2023-06-13 | 2024-12-19 | Rijksuniversiteit Groningen | Novel cdk degraders |
| WO2026067249A1 (en) * | 2024-09-29 | 2026-04-02 | K2 Medicines (Nanjing) Co., Ltd. | Cdk4 or cdk4/6 dual degrader and use thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5691147A (en) * | 1994-06-02 | 1997-11-25 | Mitotix, Inc. | CDK4 binding assay |
| US20140031325A1 (en) * | 2010-12-06 | 2014-01-30 | Celgene Corporation | Combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma |
| US20150274738A1 (en) * | 2012-10-19 | 2015-10-01 | Dana-Farber Cancer, Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6486214B1 (en) | 1997-09-10 | 2002-11-26 | Rutgers, The State University Of New Jersey | Polyanhydride linkers for production of drug polymers and drug polymer compositions produced thereby |
| SI1255752T1 (sl) | 2000-02-15 | 2007-12-31 | Pharmacia & Upjohn Co Llc | S pirolom substituirani zaviralci 2-indolinon protein kinaza |
| PL2076260T3 (pl) | 2006-09-15 | 2011-08-31 | Celgene Corp | Związki N-metyloaminometylo-izoindolu, kompozycje zawierające te związki, oraz metody ich stosowania |
| WO2008109104A1 (en) | 2007-03-07 | 2008-09-12 | The Regents Of The University Of California | Bivalent inhibitors of akt protein kinase |
| CN101918373B (zh) | 2007-07-05 | 2013-06-05 | 阵列生物制药公司 | 作为akt蛋白激酶抑制剂的嘧啶基环戊烷 |
| WO2009134418A2 (en) | 2008-04-30 | 2009-11-05 | Fox Chase Cancer Center | Assay for identifying agents that modulate epigenetic silencing, and agents identified thereby |
| EP2473054B1 (en) | 2009-09-04 | 2017-06-14 | The Regents of the University of Michigan | Compositions and methods for treatment of leukemia |
| EP2536706B1 (en) | 2010-02-11 | 2017-06-14 | Celgene Corporation | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
| CA2861066C (en) * | 2012-01-12 | 2024-01-02 | Yale University | Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an e3 ubiquitin ligase |
| US20150119435A1 (en) | 2012-05-11 | 2015-04-30 | Yale University | Compounds useful for promoting protein degradation and methods using same |
| UA118548C2 (uk) | 2012-12-21 | 2019-02-11 | Епізайм, Інк. | Тетрагідро- та дигідроізохіноліни як інгібітори prmt5 та їх застосування |
| US9796701B2 (en) | 2013-12-31 | 2017-10-24 | Xuanzhu Pharma Co., Ltd. | Kinase inhibitor and use thereof |
| WO2015104677A1 (en) | 2014-01-10 | 2015-07-16 | Piramal Enterprises Limited | Heterocyclic compounds as ezh2 inhibitors |
| AU2015247817C1 (en) | 2014-04-14 | 2022-02-10 | Arvinas Operations, Inc. | Imide-based modulators of proteolysis and associated methods of use |
| JP6744826B2 (ja) | 2014-06-13 | 2020-08-19 | バック バイオサイエンシーズ, エルエルシーBach BioSciences, LLC | Ｆａｐ活性化治療剤及びそれに関連する使用 |
| EP3885343A1 (en) | 2014-11-06 | 2021-09-29 | Dana-Farber Cancer Institute, Inc. | Indole compounds as ezh2 inhibitors and uses thereof |
| EP3227446A1 (en) | 2014-12-01 | 2017-10-11 | Novartis AG | Compositions and methods for diagnosis and treatment of prostate cancer |
| JP6815318B2 (ja) | 2014-12-23 | 2021-01-20 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | 二官能性分子によって標的化タンパク質分解を誘導する方法 |
| WO2016106518A1 (zh) | 2014-12-29 | 2016-07-07 | 深圳市日上光电股份有限公司 | 导线集成式照明灯箱 |
| AR103297A1 (es) | 2014-12-30 | 2017-05-03 | Forma Therapeutics Inc | Pirrolo y pirazolopirimidinas como inhibidores de la proteasa 7 específica de ubiquitina |
| WO2016115480A1 (en) | 2015-01-16 | 2016-07-21 | Vedantra Pharmaceuticals, Inc. | Multilamellar lipid vesicle compositions including a conjugated anaplastic lymphoma kinase (alk) variant and uses thereof |
| US10730870B2 (en) | 2015-03-18 | 2020-08-04 | Arvinas Operations, Inc. | Compounds and methods for the enhanced degradation of targeted proteins |
| EP3289074B1 (en) | 2015-04-28 | 2023-10-04 | Université de Strasbourg | Clinical gene signature-based human cell culture model and uses thereof |
| RU2719477C2 (ru) | 2015-06-22 | 2020-04-17 | Оно Фармасьютикал Ко., Лтд. | Соединение, ингибирующее brk |
| CN105085620B (zh) * | 2015-06-25 | 2018-05-08 | 中山大学附属第一医院 | 一种靶向泛素化降解Smad3的化合物 |
| WO2017007612A1 (en) | 2015-07-07 | 2017-01-12 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| WO2017011371A1 (en) | 2015-07-10 | 2017-01-19 | Arvinas, Inc | Mdm2-based modulators of proteolysis and associated methods of use |
| CA2988436A1 (en) | 2015-07-13 | 2017-01-19 | Arvinas, Inc. | Alanine-based modulators of proteolysis and associated methods of use |
| US9809603B1 (en) | 2015-08-18 | 2017-11-07 | Deuterx, Llc | Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same |
| WO2017040990A1 (en) | 2015-09-03 | 2017-03-09 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| CA3015417A1 (en) | 2016-03-01 | 2017-09-08 | Propellon Therapeutics Inc. | Inhibitors of wdr5 protein-protein binding |
| JP7624690B2 (ja) | 2016-03-01 | 2025-01-31 | プロペロン セラピューティクス インコーポレイテッド | Ｗｄｒ５タンパク質－タンパク質結合の阻害剤 |
| WO2017185031A1 (en) * | 2016-04-22 | 2017-10-26 | Dana-Farber Cancer Institute, Inc. | Degradation of cyclin-dependent kinase 4/6 (cdk4/6) by conjugation of cdk4/6 inhibitors with e3 ligase ligand and methods of use |
| EP4491236A3 (en) | 2016-05-10 | 2025-04-02 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| CN109790143A (zh) * | 2016-05-10 | 2019-05-21 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| TW201811799A (zh) | 2016-09-09 | 2018-04-01 | 美商英塞特公司 | 吡唑并嘧啶化合物及其用途 |
| US10160763B2 (en) | 2016-09-13 | 2018-12-25 | Vanderbilt University | WDR5 inhibitors and modulators |
| EP3532464A4 (en) | 2016-10-28 | 2020-07-08 | Icahn School of Medicine at Mount Sinai | COMPOSITIONS AND METHODS FOR THE TREATMENT OF EZH2 MEDIATION CANCER |
| JP2020514252A (ja) | 2016-12-08 | 2020-05-21 | アイカーン スクール オブ メディスン アット マウント シナイ | Ｃｄｋ４／６媒介性がんを治療するための組成物および方法 |
| US11052091B2 (en) | 2016-12-21 | 2021-07-06 | Ono Pharmaceutical Co., Ltd. | BRK inhibitory compound |
| WO2019113071A1 (en) | 2017-12-05 | 2019-06-13 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating alk-mediated cancer |
| WO2019165189A1 (en) | 2018-02-22 | 2019-08-29 | Icahn School Of Medicine At Mount Sinai | Protein arginine methyltransferase 5 (prmt5) degradation / disruption compounds and methods of use |
| CA3092677A1 (en) | 2018-03-06 | 2019-09-12 | Icahn School Of Medicine At Mount Sinai | Serine threonine kinase (akt) degradation / disruption compounds and methods of use |
| JP7421499B2 (ja) | 2018-05-15 | 2024-01-24 | アメリカ合衆国 | 腫瘍転移および腫瘍発生の予防および治療のための製剤および方法 |
| CA3104298A1 (en) | 2018-06-21 | 2019-12-26 | Icahn School Of Medicine At Mount Sinai | Wd40 repeat domain protein 5 (wdr5) degradation / disruption compounds and methods of use |
| CN114269749B (zh) | 2019-06-10 | 2024-10-01 | 苏特罗生物制药公司 | 5H-吡咯并[3,2-d]嘧啶-2,4-二氨基化合物及其抗体偶联物 |
| WO2021021904A1 (en) | 2019-07-30 | 2021-02-04 | The Scripps Research Institute | Pharmacological inhibitors of the enl yeats domain |
| US12103924B2 (en) | 2020-06-01 | 2024-10-01 | Icahn School Of Medicine At Mount Sinai | Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use |
| CN112778303A (zh) | 2020-12-31 | 2021-05-11 | 武汉九州钰民医药科技有限公司 | Cdk4/6激酶抑制剂shr6390的制备方法 |
-
2017
- 2017-12-07 JP JP2019530811A patent/JP2020514252A/ja active Pending
- 2017-12-07 US US16/467,888 patent/US11541051B2/en active Active
- 2017-12-07 AU AU2017370694A patent/AU2017370694A1/en not_active Abandoned
- 2017-12-07 CA CA3045037A patent/CA3045037A1/en not_active Abandoned
- 2017-12-07 EP EP17877800.7A patent/EP3551185A4/en active Pending
- 2017-12-07 CN CN201780085879.6A patent/CN110267659A/zh active Pending
- 2017-12-07 WO PCT/US2017/065027 patent/WO2018106870A1/en not_active Ceased
-
2021
- 2021-11-04 US US17/453,619 patent/US20220054488A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5691147A (en) * | 1994-06-02 | 1997-11-25 | Mitotix, Inc. | CDK4 binding assay |
| US20140031325A1 (en) * | 2010-12-06 | 2014-01-30 | Celgene Corporation | Combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma |
| US20150274738A1 (en) * | 2012-10-19 | 2015-10-01 | Dana-Farber Cancer, Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023535054A (ja) * | 2020-07-21 | 2023-08-15 | ユービックス セラピューティクス インコーポレイテッド | アンドロゲン受容体分解用化合物及びその医薬用途 |
| JP7557230B2 (ja) | 2020-07-21 | 2024-09-27 | ユービックス セラピューティクス インコーポレイテッド | アンドロゲン受容体分解用化合物及びその医薬用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017370694A1 (en) | 2019-07-25 |
| US20190336503A1 (en) | 2019-11-07 |
| EP3551185A4 (en) | 2021-07-14 |
| EP3551185A1 (en) | 2019-10-16 |
| CA3045037A1 (en) | 2018-06-14 |
| WO2018106870A1 (en) | 2018-06-14 |
| CN110267659A (zh) | 2019-09-20 |
| US20220054488A1 (en) | 2022-02-24 |
| US11541051B2 (en) | 2023-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020514252A (ja) | Ｃｄｋ４／６媒介性がんを治療するための組成物および方法 | |
| US11345714B2 (en) | Compounds targeting proteins, compositions, methods, and uses thereof | |
| US9187434B2 (en) | Substituted 1,5-benzodiazepinones compounds | |
| JP6473133B2 (ja) | Ｋｒａｓｇ１２ｃの共有結合性阻害剤 | |
| US9273014B2 (en) | Bis(fluoroalkyl)-1,4-benzodiazepinone compounds and prodrugs thereof | |
| JP2021527666A (ja) | Ｗｄ４０反復ドメインタンパク質５（ｗｄｒ５）分解／破壊化合物および使用の方法 | |
| US9427442B2 (en) | Fluoroalkyl and fluorocycloalkyl 1,4-benzodiazepinone compounds | |
| JP2022531446A (ja) | Ｈｐｋ１の分解剤としてのヘテロ二官能性化合物 | |
| WO2019113071A1 (en) | Compositions and methods for treating alk-mediated cancer | |
| JP6858984B2 (ja) | がんおよび糖尿病の治療に有用な６−ヘテロシクリル−４−モルホリン−４−イルピリジン−２−オン化合物 | |
| EP3538526A1 (en) | Cyclobutane- and azetidine-containing mono and spirocyclic compounds as alpha v integrin inhibitors | |
| JP7746259B2 (ja) | 核内受容体に対して活性の化合物 | |
| US20150232491A1 (en) | Prodrugs of 1,4-benzodiazepinone compounds | |
| AU2016214492B2 (en) | 2-phenyl-3H-imidazo[4,5-b]pyridine derivates useful as inhibitors of mammalian tyrosine kinase ROR1activity | |
| JP2021529807A (ja) | タンパク質チロシンキナーゼ６（ｐｔｋ６）分解／破壊化合物および使用方法 | |
| KR20240115978A (ko) | Lpa 수용체 길항제 및 이의 용도 | |
| US20020198189A1 (en) | New use | |
| TW202304882A (zh) | 雜環衍生物、醫藥組成物及彼等於治療或改善癌症之用途 | |
| WO2023005894A1 (zh) | 一种Wnt通路抑制剂化合物 | |
| CA3160508C (en) | Substituted ((((6-benzylamino-5-fluoropyrimidin-4-yl)amino)methyl)-piperidin-1-yl)acetamide compounds active towards nuclear receptors | |
| TW202517263A (zh) | 醫藥化合物 | |
| JP2023519603A (ja) | 核内受容体に対して活性な化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201207 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20201207 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211214 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220314 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220516 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220530 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220614 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220913 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230124 |